Mona Ashiya Sells 5,738 Shares of Disc Medicine, Inc. (NASDAQ:IRON) Stock

Disc Medicine, Inc. (NASDAQ:IRON) Director Mona Ashiya sold 5,738 shares of the firm’s stock in a transaction on Monday, March 24th. The shares were sold at an average price of $54.11, for a total value of $310,483.18. Following the transaction, the director now owns 186,541 shares of the company’s stock, valued at $10,093,733.51. The trade was a 2.98 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

Mona Ashiya also recently made the following trade(s):

• On Friday, March 21st, Mona Ashiya sold 10,011 shares of Disc Medicine stock. The shares were sold at an average price of $54.00, for a total value of $540,594.00.
• On Wednesday, March 19th, Mona Ashiya sold 39,656 shares of Disc Medicine stock. The stock was sold at an average price of $54.02, for a total transaction of $2,142,217.12.
• On Wednesday, March 12th, Mona Ashiya sold 83,182 shares of Disc Medicine stock. The shares were sold at an average price of $54.45, for a total transaction of $4,529,259.90.
• On Monday, March 10th, Mona Ashiya sold 202,146 shares of Disc Medicine stock. The stock was sold at an average price of $54.29, for a total value of $10,974,506.34.

Disc Medicine Stock Down 0.0 %

NASDAQ IRON opened at $52.47 on Friday. The business’s fifty day simple moving average is $54.75 and its 200-day simple moving average is $56.10. Disc Medicine, Inc. has a 52 week low of $25.60 and a 52 week high of $68.73. The firm has a market cap of $1.81 billion, a PE ratio of -13.18 and a beta of 0.73.

Disc Medicine (NASDAQ:IRON) last posted its earnings results on Thursday, February 27th. The company reported ($0.98) earnings per share for the quarter, beating the consensus estimate of ($1.06) by $0.08. Research analysts expect that Disc Medicine, Inc. will post -4.07 EPS for the current year.

Institutional Investors Weigh In On Disc Medicine

A number of hedge funds and other institutional investors have recently modified their holdings of the company. Sterling Capital Management LLC lifted its holdings in shares of Disc Medicine by 798.4% in the 4th quarter. Sterling Capital Management LLC now owns 566 shares of the company’s stock valued at $36,000 after purchasing an additional 503 shares during the last quarter. GF Fund Management CO. LTD. purchased a new stake in Disc Medicine in the 4th quarter valued at approximately $40,000. Tower Research Capital LLC TRC grew its holdings in Disc Medicine by 47.6% during the fourth quarter. Tower Research Capital LLC TRC now owns 825 shares of the company’s stock worth $52,000 after acquiring an additional 266 shares during the period. Quest Partners LLC purchased a new position in shares of Disc Medicine in the 3rd quarter valued at about $131,000. Finally, Quantbot Technologies LP purchased a new position in Disc Medicine in the third quarter valued at about $146,000. 83.70% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of research analysts recently commented on IRON shares. TD Cowen began coverage on Disc Medicine in a research note on Thursday, February 27th. They issued a “buy” rating for the company. Scotiabank lifted their price target on Disc Medicine from $73.00 to $75.00 and gave the stock a “sector outperform” rating in a research report on Monday, March 3rd. Cantor Fitzgerald boosted their price objective on shares of Disc Medicine from $99.00 to $132.00 and gave the company an “overweight” rating in a research report on Tuesday, March 18th. Stifel Nicolaus upped their target price on Disc Medicine from $90.00 to $94.00 and gave the company a “buy” rating in a research note on Friday, January 24th. Finally, Wedbush reaffirmed an “outperform” rating and issued a $90.00 price target (up previously from $83.00) on shares of Disc Medicine in a research note on Tuesday, January 21st. Ten investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus price target of $93.80.

Disc Medicine Company Profile

Disc Medicine, Inc, together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis.